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Objective
Chronic mild elevations of liver enzymes are frequently 
encountered in type 2 diabetes mellitus.1-2 Some studies 
have shown that markers of liver injury can independently 
predict type 2 diabetes mellitus.3 The aetiology of liver 
function test (LFT) derangements in type 2 diabetes mellitus 
may be quite varied. Non-alcoholic fatty liver disease 
(NAFLD) is often associated with LFT abnormalities. The 
reported prevalence of NAFLD in type 2 diabetes mellitus 
ranges from 30-75% and is almost universally associated 
with morbidly obese subjects with diabetes.4-6 Therefore the 
frequency of such abnormalities in type 2 diabetes mellitus 
is not at all surprising. 
A further contributor to LFT derangements in such patients 
is drug therapy. Statins are frequently prescribed to reach 
low-density lipoprotein (LDL) and high-density lipoprotein 
(HDL) cholesterol targets in subjects with type 2 diabetes 
mellitus. Hepatotoxicity is a known complication of statin 
therapy, especially in those treated with high doses, and if 
used in combination with a fibrate. Routine LFT monitoring 
in this situation is common practice. Oral antidiabetic 
agents, such as sulphonylureas, thiazolidinediones and 
alpha-glucosidase inhibitors, may also cause hepatic 
injury with resultant LFT derangements.7-10 Deranged liver 
enzymes, related to poor diabetes control, have also been 
described.11 In some of these cases, hepatic glycogenosis 
has been shown to be the cause.12
Also of significance is the high frequency of transaminase 
abnormalities in obese patients with type 2 diabetes. This 
probably reflects the strong association between obesity 
and NAFLD; insulin resistance is the common factor. 
With the worldwide prevalence of obesity on the rise, the 
incidence of diabetes is also expected to escalate, and 
presumably LFT abnormalities will be more commonly 
encountered in diabetes clinics. Although the prevalence of 
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Abstract
Objective: To determine the prevalence of liver function test abnormalities in South African black and Indian adult patients 
with type 2 diabetes mellitus attending a tertiary diabetes clinic.
Method: The study was a retrospective chart review of patients with type 2 diabetes attending a diabetes clinic. Recorded 
data included the past medical and drug history, history of alcohol abuse, anthropometry, lipid profile and liver function tests. 
Results: The charts of 313 patients were reviewed. Liver function test abnormalities were found in 146 patients (46.6%). 
Of these,15 patients had a history of alcohol abuse, or a past medical history that might explain the abnormality, and these 
patients were excluded from further analysis. Elevations in serum gamma-glutamyl transferase, alkaline phosphatase and 
alanine transaminase were found in 25.2% (n = 79), 23.3% (n = 73) and 15.3% (n = 48), respectively. Serum total cholesterol, 
triglycerides and low-density lipoprotein cholesterol were higher in the group with liver function test abnormalities when 
compared with subjects with normal results. Mean body mass index was similar in the two groups (32.5 vs. 33.2 kg/m2). 
Although morbidly obese patients (n = 42) demonstrated the highest frequency of liver enzyme derangements (54.8%), this 
was not statistically significant. 
Conclusion: There is a high prevalence of liver function test abnormalities in this group of patients with type 2 diabetes, and 
this is particularly so in the morbidly obese subjects. This is comparable with the reported prevalence in the Western world. 
Lipid abnormalities were more frequent in the group with liver enzyme derangements.
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LFT abnormalities in type 2 diabetes mellitus has been well 
documented in Western populations, there is a paucity of 
data from developing countries and a lack of information 
from South Africa.1,2,13,14
The purpose of this study was to determine the prevalence 
of asymptomatic LFT abnormalities in South African black 
(African origin) and Indian patients with type 2 diabetes 
mellitus, attending a tertiary referral adult diabetes clinic.
Method
The study was a retrospective chart review of patients with 
type 2 diabetes mellitus attending the diabetes clinic at 
Inkosi Albert Luthuli Central Hospital (IALCH) in Durban, 
KwaZulu-Natal. The charts of all the patients attending the 
clinic between January 2004-October 2007 were reviewed. 
For each subject, demographic details, clinical findings and 
laboratory results were recorded, including age, gender 
and duration of diabetes. The past medical history was 
reviewed to explain abnormal liver enzymes. In particular, a 
history of alcohol abuse, primary biliary cirrhosis, sclerosing 
cholangitis, haemochromatosis, congestive cardiac failure, 
chronic active hepatitis and viral hepatitis was sought. The 
use of any one of the following drugs was also noted: statins, 
fibrates, thiazolidinediones, metformin, sulphonyureas and 
insulin.
Anthropometric data included height and weight for 
calculation of the body mass index (BMI) [weight (kg)/height 
(m2)].15 Patients were categorised according to the following 
BMI groups for comparison: normal weight (BMI < 25 kg/
m2), overweight and obese (BMI > 25 kg/m2), obese (BMI 
> 30 kg/m2) and morbidly obese (BMI > 40 kg/m2). 
The following laboratory tests were recorded: liver function 
tests [serum total protein, albumin, bilirubin, alkaline 
phosphatase (ALP), alanine transaminase (ALT), gamma-
glutamyl transferase (GGT)]; serum lipids (total cholesterol, 
HDL cholesterol, LDL cholesterol, total triglyceride) and 
haemoglobin A1C (HbA1C).
Liver enzymes were defined as abnormal if the concentration 
exceeded the upper limit of normal (ULN) for the reference 
range. The prevalence of abnormal liver enzymes (ALE) was 
calculated in the total study group. Patients with a history of 
alcohol abuse or liver disease, including those with a past 
medical history, were excluded from further analysis. The 
remaining group, all of whom had unexplained ALE, were 
stratified according to gender, ethnicity, BMI category and 
drug usage.
The severity of ALE was also categorised by the degree of 
elevation above normal. The ALE severity was compared 
with the group experiencing any increase in ALE above the 
upper limit of normal (ULN). The three categories of ALE 
included: 
• Greater than 1.5 times above the ULN (> 1.5 x ULN); 
• Between 1-2.5 times the ULN (1-2.5 x ULN); and
• Greater than 3 times the ULN (> 3 x ULN). 
The severity of ALE was then assessed and compared 
across the spectrum of BMI categories.
The Roche/Hitachi Modular® analyser was used to measure 
liver enzymes. The coefficient of variation for ALP, ALT and 
GGT assays was 17.5%, 8.6% and 1.8% respectively. 
Normal reference ranges (IU/L) were as follows: males (ALP 
40-129; GGT 8-61; ALT 1-41) and females (ALP 35-104; 
GGT 5-36; ALT 1-31).
The study was approved by the Nelson R Mandela School 
of Medicine ethics committee. 
Statistical analysis
Categorical variables were compared with the c2 test, and 
Student’s two-tailed t-test was used to detect continuous 
variables. Data are presented as mean ± standard deviation 
(SD) or as a percentage (%). A p-value < 0.05 was considered 
significant. 
Results
A total of 313 charts were reviewed, of which 98 (31.3%) 
were those of male patients and 215 (68.9%) were those of 
female patients. Black and Indian patients represented the 
largest ethnic groups (38.4% and 55.9%) of the total study 
group. Table I shows the characteristics of the total study 
group. The mean age was 57.7 ± 12.5 years, mean diabetes 
duration 15.7 ± 10.3 years and mean HbA1C 9.2 ± 2.1%.
Liver enzyme levels above ULN were found in 146 patients 
(46.6%). Of these, 15 patients were excluded from further 
analysis due to a past medical history that could have 
explained the abnormality (14 with alcohol abuse, and one 
with chronic liver disease). Unexplained ALE was found in 
131 patients (41.8%). 
Of the total group (n = 313), the most frequent ALE was 
a raised GGT, occurring in 25.2% of patients (n = 79). 
Derangements in ALP and ALT were noted in 23.3% 
(n = 73) and 15.3% (n = 48) of patients respectively (Table 
I). The majority of these derangements were mild, with 22% 
of patients having ALE > 1.5 times the ULN, 33% with ALE 
between 1-2.5 times the ULN, 9% with ALE > 2.5 times the 
ULN, and 6% with ALE > 3 times the ULN. 
Table II shows a comparison between the group with 
unexplained ALE (n = 131) and the group without ALE 
(n = 167). The prevalence of abnormal liver enzymes above 
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the ULN was similar between genders and the different 
ethnic groups. Patients with ALE had significantly higher 
mean serum total triglycerides and LDL-cholesterol (p-value 
< 0.05). No difference was observed between the two 
groups with regard to age, duration of diabetes, HbA1C and 
other lipid levels.
Of the drugs commonly utilised in the management of type 
2 diabetes mellitus, only fibrate use was associated with 
ALE prevalence (Table III). Bezafibrate was prescribed to 
3.2% (n = 10) of the total study group and all 10 patients 
(100%) had ALE above the upper limit of normal. However, 
these derangements were mild (< 2.5 times the ULN). 
Patients on bezafibrate had higher serum total triglycerides 
and total cholesterol when compared to those who were 
not receiving this therapy (triglycerides 8.54 ±7.1 mmol/l 
vs. 2.1 ±1.4 mmol/l, p-value < 0.05; total cholesterol 6.39 
±1.8 mmol/l vs. 4.8 ±1.2 mmol/l, p-value < 0.05).
There was an increase in the prevalence of ALE above the 
ULN with higher BMI. Rates in the normal weight, overweight 
and obese, obese and morbidly obese BMI groups were 
42%, 47%,46% and 55% respectively. However, the 
difference was not statistically significant (Figure 1).
The prevalence of ALE in the different BMI categories 
was examined with regard to severity of derangements. 
There was a non-significant rise in the prevalence of ALE 
with increasing BMI category noted with ALE ≤ 2.5 times 
Table I: Characteristics of the total study group (n = 313)
Variablea
Gender (male:female) [n (%)] 98:215 (31.3:68.9)
Ethnicity [n (%)]
  Black 120 (38.3)
  Indian 175 (55.9)
  White 13 (4.1)
  Coloured 5 (1.6)
Age (in years)                    57.7 + 12.5
Diabetes duration (in years)         15.7 + 10.3
BMI (kg/m2)b                 32.5 + 7.1
HbA1c (%)
c                   9.2 + 2.1
Drug history [n (%)]
  Fibrate                  10 (3.2)  
  Statin                   200 (63.6) 
  Thiazolidinedione          1 (0.3)
  Sulphonylurea            137 (43.7)
  Metformin                178 (56.8)
  Insulin                   211 (67.4)
Serum lipid (mmol/l)
  Total cholesterol            4.9 + 1.3 
  Total triglyceride            2.3 + 2.2
  HDLd cholesterol           1.3 + 0.4
  LDLe cholesterol            2.6 + 0.9
Serum LFTf variables (IU/L)
  Alkaline phosphatase   93.9 + 30.4
  Gamma-glutamyl transferase 45.9 + 59.9 
  Alanine transaminase      29.4 + 30.9                         
Unexplained serum ALEg [n (%)] 131 (41.8)
Elevated serum liver enzymes [n (%)]    
  Alkaline phosphatase 73 (23.3)
  Gamma-glutamyl transferase   79 (25.2)
  Alanine transaminase 48 (15.3)
a = values expressed as means (standard deviation) or n (%) 
b = body mass index
c = haemoglobin A1c 
d = high-density lipoprotein 
e = low-density lipoprotein
f = liver function test
g = abnormal liver enzymes
Table II: Comparison between type 2 diabetes patients with normal  
(n = 167) and unexplained abnormal liver enzymes (n = 131)
Variablea
Normal liver enzymes Abnormal 
liver 
enzymes
(n = 167) (n =131)
Age (in years) 58.0 + 12.8 57.3 + 12.3
Gender [n (%)]
  Male 59 (35.3)  26 (19.8)
  Female 108 (64.7) 105 (80.2)
Ethnicity [n (%)]
  African 71 (42.5) 49 (37.4)
  Indian 87 (52.1) 75 (57.3)
  White 7 (4.2) 6 (4.6)
  Coloured 2 (1.2) 3 (2.3)
BMIb category [n (%)]
  Normal weight 22 (13.2) 12  (9.2)
  Overweight and obese 145 (86.8) 119 (90.8)
  Obese 103 (61.7) 85  (64.9)
  Morbidly obese 19  (11.4) 23  (17.6)
Diabetes duration (in years) 15.76 + 11.0 15.35 + 9.1
HbA1c
c
 (%) 9.06 + 2.05 9.30 + 2.06
Lipid profile (mmol/l)
  Total cholesterol 4.6 + 1.0 5.2 + 1.4
  Total triglyceride 1.9 + 1.1 2.8 + 2.8d
  HDLe cholesterol 1.3 + 0.3 1.4 + 0.4
  LDLf cholesterol 2.4 + 0.8 2.8 + 1.0d
Liver enzymes (IU/L)
  Alkaline phosphatase                    
  Gamma-glutamyl transferase
  Alanine transaminase
      
 80.7 + 16.3
 22.8 + 9.5




a = values expressed as means (standard deviation) or n (%)
b = body mass index
c
 = haemoglobin A1c
d = p-value < 0.05
e = high-density lipoprotein 
f = low-density lipoprotein
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the ULN. (Figure 1).The prevalence of ALE between 1-2.5 
times the ULN in the overweight, obese and morbidly obese 
groups, was 33%, 34% and 45%, respectively. This trend 
was not observed with more severe abnormalities (above 
2.5 times the ULN). The prevalence of ALE above 2.5 times 
the ULN in the overweight, obese and morbidly obese 
groups was 8%, 10% and 10% respectively.
Discussion
This study, of predominantly South African black and Indian 
patients with type 2 diabetes mellitus, has shown a high 
prevalence (42%) of unexplained ALE, a finding similar to 
the reported prevalence in Western populations.
Although deranged LFTs in type 2 diabetes mellitus have 
been reported for over two decades, these are limited to a 
few reports emanating mainly from Western countries, with 
little or no data available from African countries, including 
South Africa. In an earlier study, which included 175 
unselected Finnish patients with type 1 and type 2 diabetes, 
Salmela et al reported that the prevalence of ALE was 57%.1 
Recent studies have confirmed the high prevalence of ALE 
in patients with type 2 diabetes mellitus, with rates ranging 
from 15-30%.13-14
In patients with asymptomatic ALE, NAFLD was the most 
common diagnosis when detailed investigations were 
conducted, accounting for 64-90% of cases.18-20 Although 
the aetiology of ALE in patients with type 2 diabetes mellitus 
may be varied, the most common cause is assumed to be 
NAFLD. In general, the prevalence of NAFLD has been 
shown to be high in patients with type 2 diabetes mellitus, 
and is almost universal in morbidly obese subjects with type 
2 diabetes mellitus.4-6
In this study, the most frequently encountered abnormalities 
were those of GGT and ALP, rather than ALT abnormalities. 
The few available reports have highlighted ALP as the 
most frequent abnormality in subjects with type 2 diabetes 
mellitus and ALE.1,13 However, this is not a universal finding 
and transaminase abnormalities have been shown to be 
the most common abnormality in some studies.14 Higher 
transaminases would be more suggestive that NAFLD is the 
probable cause in such patients. However, since a recent 
history of alcohol intake was not available, the possibility 
that this may have contributed to the higher prevalence of 
ALP and GGT abnormalities in the present study cannot be 
excluded.
Lipid abnormalities were more frequently encountered in 
patients with ALE when compared to patients with normal 
liver enzymes. The two abnormalities that were associated 
with ALE included a higher serum total triglyceride and 
LDL cholesterol. Considering that hepatic steatosis is 
common in patients with type 2 diabetes mellitus, it is of 
interest that hepatic steatosis has been shown to influence 
both the severity and composition of dyslipidaemia.16 
Toledo et al demonstrated that hepatic steatosis, as 
detected by computed tomography, predicted more severe 
dyslipidaemia in men and women with type 2 diabetes 
mellitus. In the present study, pooling patients with ALE from 
a group of subjects with type 2 diabetes mellitus may have 
resulted in a higher proportion of patients with NAFLD being 
selected. Hence, the higher frequency of lipid abnormalities 
in the ALE group in the present study would be compatible 
with the findings of Toledo and colleagues.
Forlani et al have previously shown that elevated 
triglycerides and fibrate treatment were independently 
associated with a high ALT.13 An unusually high frequency of 
ALE among patients on fibrate therapy was also observed 
in this small group of patients. Of importance is that all the 
derangements were mild, drawing attention away from drug-
induced hepatotoxicity as the likely culprit, and implicating 
an alternate aetiology.
Table III: Prevalence of abnormal liver enzymes (ALE) according to drugs 
prescribed in patients with type 2 diabetes (n = 313)
                 n (%)
Receiving drug therapy 
of total with ALEa
   Not receiving drug 
therapy of total with ALEa
Fibratesb 10 (3.2)         10 (100.0) 303 (96.8) 136 (44.8)
Statin 200 (63.8)    92 (46.0) 113 ( 36.1) 54 (47.7)
TZDc 1 (0.3)          1 (100) 312 (99.7) 145 (46.5)
SUd 137 (43.8)    67 (48.9) 176 (56.2) 79 (44.9)
Metformin 178 (56.9)    78 (43.8) 135 (43.1) 68 (50.4)
Insulin 211 (67.4)      102 (48.3) 102 (32.6) 44 (43.1)
a = abnormal liver enzymes
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Figure 1: Body mass index and severity of abnormal liver enzymes in 
patients with type 2 diabetes mellitus
ULN: upper limit of normal
BMI category (kg/m2): OW 25-30; OW+OB > 25; OB > 30; morbid OB > 40
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In terms of the severity of ALE recorded in this study, the 
majority of liver enzyme derangements were mild, between 
1-2.5 times the ULN. More severe derangements were less 
frequent, and only 9% and 6% of the total study group had 
ALE above 2.5 times and 3 times the ULN respectively. 
Since most studies have not reported on the severity of 
ALE, the exact implications of this finding are not known. 
However, it may be inferred that, in this study, the cause 
of the ALE is less likely due to drug-induced hepatotoxicity 
or viral hepatitis, where one would expect more severe 
derangements, in particular, the transaminases.21-22 
Although the full spectrum of liver enzyme abnormalities 
may be observed with NAFLD, mild derangements, such as 
that noted in this study, are more frequently encountered 
with hepatic steatosis. 
Previous reports have documented a higher prevalence of 
ALE with increasing BMI category.1,13,17 The likely explanation 
for this observation is a rising prevalence of NAFLD with 
increasing BMI. In this study, there was a trend toward a rise 
in prevalence of ALE with increasing BMI category, but this 
was only noted for mild derangements, and not for the more 
severe abnormalities (ALE > 2.5 times and > 3 times the 
ULN). This trend may be explained by the lower probability 
of severe derangements in liver function being attributable 
to NAFLD. More severe derangements in liver function are 
more likely to be due to factors other than NAFLD, and 
therefore unrelated to BMI.
Conclusion
In conclusion, the results of this study are in accordance 
with previously reported high prevalence rates of ALE in 
patients with type 2 diabetes mellitus in other populations. 
Although there are currently no consensus guidelines or 
recommendations regarding LFT screening in patients with 
type 2 diabetes mellitus, these findings lend support to the 
practice of routine liver function monitoring in subjects with 
type 2 diabetes mellitus. Furthermore, the high prevalence 
of severe derangements also highlights the importance of 
performing LFTs in these otherwise asymptomatic patients, 
as they may harbour potentially treatable co-morbid illnesses. 
Many of these patients would require further laboratory, 
radiological and histological investigation. Therefore, if LFT 
screening is to be adopted, it would be incumbent on the 
physician to ensure that abnormal findings are appropriately 
investigated, or that the patient be timeously referred to a 
tertiary institution with the necessary facilities.
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